首页 News 正文

New players have been added to the field of electric field therapy for tumors. AstraZeneca and Haier have jointly explored new treatment options for gastrointestinal tumors

无由窗置
1170 0 0

On September 5th, AstraZeneca and Jiangsu Hailai Xinchuang Medical Technology Co., Ltd. (hereinafter referred to as Hailai Xinchuang) officially signed a clinical research cooperation agreement. According to the agreement, both parties will jointly carry out clinical research on the application of AstraZeneca immune checkpoint inhibitors combined with Hailey Xinchuang electric field therapy in solid tumors such as gastrointestinal tumors represented by biliary malignancies.
Tumor Treating Fields (TTF) is an innovative physical therapy modality for tumors. Previously, as a pioneer in tumor electric field therapy, Novocure's product Optune was currently the only globally approved product for market launch. In July 2020, Optune was introduced to the domestic market through Zaiding Medical. That year, Zaiding Medical's market value doubled, and Optune became the company's second largest pipeline, with a net revenue growth of 300%. Afterwards, Optune continued to grow at an annual rate of around 10%.
The tumor treatment electric field is currently in the import stage in China. Apart from Optune, which has been approved for the treatment of glioblastoma in China, there are no domestically produced products on the market yet. However, companies in China, including Jiangsu Hailai Xinchuang, Hunan Antaikang, and Zhejiang Saifukaier, are laying out in this emerging field.
Among them, the tumor electric field therapy device EFE-G100 independently developed by Hailai Xinchuang has been recognized as an innovative medical device by the National Medical Products Administration and is currently conducting multi center clinical trials. Hailai Xinchuang has also become the first TTF research and development enterprise in China and the second in the world to enter the multi center clinical stage.
From now on, the collaboration between AstraZeneca and Haier Innovation not only expands the application of electric field therapy in a wider range of tumor fields, but also sets a new paradigm for clinical research on drug combination innovative tumor treatment devices.
It is reported that, in addition to this cooperation, AstraZeneca will promote the clinical research of combined treatment of third-generation EGFR-TKI ohitinib, targeted HER2 ADC dtriazumab (developed in cooperation with the First Three Communist Party of China), immunocheckpoint inhibitors (including Tremelimumab and Duvalizumab), and the new BTK inhibitor achotinib, covering gastrointestinal tumors, lung cancer, breast cancer, blood tumors and other fields. As of now, more than 20 local pharmaceutical companies have applied and reached cooperation agreements with five Chinese local enterprises, including Shiyao Group and Yasheng Pharmaceutical, for joint treatment clinical research.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    6 小时前
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    前天 19:48
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    前天 20:09
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    半小时前
    支持
    反对
    回复
    收藏
无由窗置 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    1